Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis

Diabetes, Obesity & Metabolism
Panagiotis AndreadisApostolos Tsapas

Abstract

To assess the efficacy and safety of semaglutide, a recently approved glucagon-like peptide 1 receptor agonist (GLP-1 RA) for type 2 diabetes. We searched major electronic databases and grey literature sources for randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents. Primary outcome was change from baseline in HbA1c. Secondary endpoints included change from baseline in body weight, blood pressure, heart rate and incidence of hypoglycaemia, gastrointestinal adverse effects, pancreatitis and diabetic retinopathy. A total of 6 placebo-controlled and 7 active-controlled studies with subcutaneous semaglutide were included. We identified only 1 trial with oral semaglutide. Compared with placebo, subcutaneous semaglutide 0.5 and 1 mg reduced HbA1c by 1.01% (95% CI, 0.56-1.47) and 1.38% (1.05-1.70), respectively. Both doses demonstrated superior glycaemic efficacy compared to other antidiabetic agents, including sitagliptin, exenatide, liraglutide, dulaglutide and insulin glargine. Semaglutide also had a beneficial effect on body weight (mean difference vs placebo -4.11 kg, 95% CI -4.85 to -3.37 for semaglutide 1 mg) and systolic blood pressure. We did not observe increased hypoglycaemia rates wi...Continue Reading

References

Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Aug 8, 2007·Annals of Internal Medicine·George A DiamondSanjay Kaul
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Nov 28, 2017·Diabetes, Obesity & Metabolism·Tina VilsbøllMichael Larsen
Feb 6, 2018·The Lancet. Diabetes & Endocrinology·Richard E PratleyUNKNOWN SUSTAIN 7 investigators

❮ Previous
Next ❯

Citations

Aug 24, 2018·Diabetes, Obesity & Metabolism·Gian Paolo FadiniUNKNOWN DARWIN-T2D Network
Feb 16, 2019·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·Georgios A ChristouDimitrios N Kiortsis
Sep 26, 2019·Heart·Gaurav S GulsinGerry P McCann
Oct 23, 2019·Diabetes, Obesity & Metabolism·Ioannis AvgerinosEleni Bekiari
May 20, 2020·Expert Opinion on Drug Safety·Rajesh Peter, Steve C Bain
Oct 28, 2019·Chronic Illness·Anastasia-Stefania AlexopoulosMatthew J Crowley
Jun 2, 2020·Expert Review of Clinical Pharmacology·Richard A Chudleigh, Stephen C Bain
Sep 11, 2020·Journal of Clinical Pharmacy and Therapeutics·Jennifer D Goldman
Jul 31, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sanjay KalraManilka Sumanatilleke
Nov 7, 2019·Current Diabetes Reports·Patricia R Peter, Beatrice C Lupsa
Jun 15, 2020·Current HIV/AIDS Reports·Aaren KettelhutNicholas T Funderburg
Jun 2, 2020·Advanced Drug Delivery Reviews·D J BraydenR J Mrsny
Nov 11, 2020·Journal of Diabetes and Its Complications·Gustavo Monteiro EscottSandra Pinho Silveiro
Mar 9, 2021·Endocrinology and Metabolism·Hun Jee Choe, Young Min Cho
Mar 26, 2021·British Journal of Pharmacology·Johanna HelmstädterSebastian Steven
Jul 1, 2019·Metabolism: Clinical and Experimental·Anastasia-Stefania Alexopoulos, John B Buse
Jul 17, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sanjay KalraNitin Kapoor
Sep 8, 2021·Journal of Comparative Effectiveness Research·Margaret F ZupaKenneth J Smith

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.